A
Alcista
Alcista · 25%HALO
$80.41
Precio del escenario
$125.630
+1.106 (+0.88%)Al cierre
Loading chart…
- Máximo
- 126.230
- Apertura
- 124.540
- Precio medio ponderado por volumen
- 125.20
- Volumen
- 1.53M
- Capitalización
- —
- Mínimo
- 123.740
- Importe
- 191.60M
- EV/EBITDA, TTM
- 11.76
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
Análisis de IA of Halozyme Therapeutics Inc (HALO)
ComprarHalozyme Therapeutics Inc (HALO) is a good buy right now, with a current price of $125.63 and a forward P/E of 11.45, indicating strong growth potential compared to its earnings. The stock has shown a remarkable year-to-date change of +78.68%, reflecting robust market confidence. However, a key risk is the significant insider selling, which has increased by 4215.85% over the last quarter, indicating potential concerns among insiders about future performance.
Recomendaciones de analistas (10)
-37.51% Potencial de caída
Comprar
7 Comprar
2 Mantener
1 Vender
Actual: 125.63
Mínimo
56.00
Promedio
78.50
Máximo
90.00
H.C. Wainwright
Comprar
$130
2026-10-08
H.C. Wainwright
2026-10-08
Precio objetivo
$130
Comprar
JPMorgan
Neutral
$78
2026-10-08
JPMorgan
2026-10-08
Precio objetivo
$78
Neutral
H.C. Wainwright
Comprar
$115
2026-09-02
H.C. Wainwright
2026-09-02
Precio objetivo
$115
Comprar
TD Cowen
Comprar
$105
2026-08-07
TD Cowen
2026-08-07
Precio objetivo
$105
Comprar
Wells Fargo
Equal Weight
$95
2026-08-07
Wells Fargo
2026-08-07
Precio objetivo
$95
Equal Weight
Métricas de valoración
El PER previsto actual de Halozyme Therapeutics Inc (HALO) es 11.45, frente a su media de 5 años de 12.63.
Escenarios de precio de Alphio AI para HALO
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con HALO en cartera
Cronología de eventos
Noticias
9.510-22PRnewswireHalozyme to Release Q3 2026 Financial Results
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
5.010-14CNBCMerck's New Vaccine Manufacturing Accelerates
7.010-07PRnewswireDutch Court Rules Merck Infringes Halozyme Patent
7.510-06PRnewswireargenx Expands Collaboration Agreement with Halozyme
Preguntas frecuentes sobre HALO, respondidas por Alphio AI
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Halozyme Therapeutics Inc (HALO) is a good buy right now, with a current price of $125.63 and a forward P/E of 11.45, indicating strong growth potential compared to its earnings. The stock has shown a remarkable year-to-date change of +78.68%, reflecting robust market confidence. However, a key risk is the significant insider selling, which has increased by 4215.85% over the last quarter, indicating potential concerns among insiders about future performance.
10 analysts cover HALO: 7 rate it Buy, 2 Hold and 1 Sell. The average price target is 78.50.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.